Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. iv dosing
Show results for
Products

Companies

News

Refine by
Date

  • Older

Iv Dosing Articles & Analysis

8 news found

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Specific results include the following: Positive effects on lactate and pH were observed with the TSC 2.5 mg/kg dose at the end of the exercise period versus the baseline measurement. ...

ByCervoMed


OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression

OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression

” The Veloxis study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of VEL-101 or placebo when administered subcutaneously (SC) or intravenously (IV). ...

ByOSE Immunotherapeutics


Actym Therapeutics Announces Significant Expansion of Senior Leadership

Actym Therapeutics Announces Significant Expansion of Senior Leadership

Actym Therapeutics, a privately held biotechnology company developing STACT, a novel therapeutic platform that delivers immunomodulatory payloads to solid tumors after IV dosing, announced today the significant expansion of its senior leadership team. ...

ByActym Therapeutics


Actym Therapeutics Announces Lead Candidate for Clinical Development, Presentation at SITC

Actym Therapeutics Announces Lead Candidate for Clinical Development, Presentation at SITC

Complete tumor responses were observed in metastatic, checkpoint refractory tumors (IV dosing), that were entirely dependent on CD8+ T-cells. In primates, the therapy was well tolerated, rapidly cleared, and elicited minimal cytokine responses after IV dosing. ...

ByActym Therapeutics


PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T-SIGn vector, NG-350A, to Re-Engineer Advanced Cancers

PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T-SIGn vector, NG-350A, to Re-Engineer Advanced Cancers

Key data from the first-in-human FORTITUDE trial shows that a single cycle of intravenous (IV) NG-350A drives dose-dependent increases in specific inflammatory biomarkers, consistent with the mechanism of the encoded anti- CD40 agonist. IV dosing of NG-350A led to elevations in IL-12, IFNγ and IL-17 that were higher and ...

ByPsiOxus Therapeutics Ltd.


Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy

Ascelia Pharma presents clinical development plan for Oncoral as a novel chemotherapy

Today, the administration of irinotecan is intravenous (IV) bolus infusions, typically as a high dose every third week. Oncoral is a novel patented tablet formulation of irinotecan for daily dosing at home with potential to offer better patient outcomes. ...

ByAscelia Pharma AB


Actym Therapeutics Raises $34 Million Series A ?

Actym Therapeutics Raises $34 Million Series A ?

Actym’s platform technology allows for the delivery of multiplexed immunological payloads to the tumor microenvironment (TME) after IV dosing, in a single therapeutic composition. This financing, from an esteemed group of investors, is a key validation of our approach,” said Dr. ...

ByActym Therapeutics


Actym Therapeutics Will Present Data at the 2019 Society for the Immunotherapy of Cancer (SITC) Annual Meeting

Actym Therapeutics Will Present Data at the 2019 Society for the Immunotherapy of Cancer (SITC) Annual Meeting

The presentation is entitled “STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to Tumor-Resident Myeloid Cells After IV Dosing and Demonstrates Potent Anti-Tumor Efficacy in Preclinical Studies”. ...

ByActym Therapeutics

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT